Small cell lung cancer(SCLC)belongs to neuroendocrine malignancy and indicates an extremely poor prog-nosis.Concurrent chemoradiotherapy and first-line chemotherapy of SCLC rely on traditional medication such as etoposide and platinum,and the options after first-line treatment resistance are limited.In recent years,immunotherapy has emerged in the field of SCLC.Immunotherapy combined with chemotherapy has become the first-line standard of care for extensive-stage SCLC.ASTRUM-005 and CAPSTONE-1 studies confirmed that serplulimab and adebrelimab further prolonged the survival time of extensive-stage SCLC patients.Antivascular therapy has offered a new option for third-line or subsequent treatment of SCLC.Immunotherapy combined with antivascular therapy is advancing to the first-line treatment of exten-sive-stage SCLC,and is being explored in limited-stage SCLC.The development of limited-stage SCLC treatment has been slow.Some clinical researches on optimal timing,radiation dose and fractionation pattern of thoracic radiotherapy have made some progress.But the role of prophylactic cranial irradiation in limited-stage SCLC has been questioned by some clinical evidences.New medicine such as delta-like ligand 3(DLL3)inhibitors and poly-ADP ribose polymerase(PARP)inhibitors gradually emerged,hoping to bring new breakthroughs in the treatment of SCLC.Meanwhile,the prelimi-nary determination of molecular subtypes of SCLC is essential for precision therapy.Exploration of immunotherapy pattern in limited-stage SCLC,new immune checkpoint inhibitor medicine and different combination therapy strategies are de-signed in clinical trials for SCLC population.This review aims to summary the new advances in the treatment of SCLC.
Small cell lung cancerImmunotherapyRadiotherapyAntivascular therapy
国家科技期刊平台
NSTL
万方数据
